A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Recruiting now Phase 2 NCT07033494
Run by Merck Sharp & Dohme LLC · for 50 to 85 · All sexes
What this study is about
Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD. The goals of the study are to learn: * If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment. * About the safety of MK-2214 and if people tolerate it
Who can join (things the study team will check)
✅ You may be able to join if…
- Has mild cognitive impairment (MCI) or mild dementia due to Alzheimer's Disease (AD)
- Has a designated study partner who can fulfill the requirements of this study
- If on an approved AD therapy for symptomatic AD, the dosing regimen must have been stable for 3 months prior to screening
🚫 You may not be able to join if…
- Has a known history of stroke or cerebrovascular disease
- Has diagnosis of a clinically relevant central nervous system disease other than AD or other condition that negatively impacts cognition or cognitive status chronically
- Has structural brain disease
- Has a history of seizures or epilepsy within 5 years before screening
- Has any other major central nervous system trauma, or infections that affect brain function
- Has major medical illness or unstable medical condition within 3 months before screening
- Has a severe, acute, or chronic medical or psychiatric condition or laboratory abnormality
- Has any immunological disease, which is not adequately controlled, or which requires treatment with biologics and/or immunosuppressants during the study
- Has a bleeding disorder that is not under adequate control
- Has a history of malignancy occurring within 5 years of screening
- Has a risk factor for corrected QT interval (QTc) prolongation
- Has liver disease
- Is unwilling or unable to undergo computed tomography (CT), positron emission tomography (PET), or magnetic resonance imaging (MRI) scan
- Resides in a nursing home or assisted care facility with need for direct continuous medical care and nursing supervision
Where this trial is running
- Irvine Clinical Research ( Site 1041), Irvine, California, United States
- Healthy Brain Clinic ( Site 1005), Long Beach, California, United States
- Inglewood Clinical ( Site 1062), Los Angeles, California, United States
- Anderson Clinical Research ( Site 1024), Redlands, California, United States
- UCSF Memory and Aging Center ( Site 1031), San Francisco, California, United States
- Syrentis Clinical Research ( Site 1001), Santa Ana, California, United States
- Yale University, Alzheimer's Disease Research Unit ( Site 1059), New Haven, Connecticut, United States
- JEM Research Institute ( Site 1046), Atlantis, Florida, United States
- Neuropsychiatric Research Center of Southwest Florida ( Site 1003), Fort Myers, Florida, United States
- K2 Medical Research ( Site 1047), Maitland, Florida, United States
- ClinCloud LLC ( Site 1039), Melbourne, Florida, United States
- Indago Research and Health Center Inc ( Site 1044), Miami Lakes, Florida, United States
+ 67 more sites.
Who to contact
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07033494.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.